Wegovy (semaglutide) was the first of the newer GLP-1 weight loss medications to receive NICE approval for use on the NHS, in March 2023 under technology appraisal TA875. However, "available on the NHS" and "easy to access on the NHS" are two very different things.1

How NHS access works for Wegovy

Unlike Mounjaro (which is being rolled out through GP practices in a phased approach), Wegovy on the NHS is primarily available through Tier 3 specialist weight management services. These are hospital-based or specialist community services that provide structured, multidisciplinary weight management programmes including dietary support, psychological input, and medical supervision.1

You generally need a GP referral to access Tier 3 services. Your GP will assess whether you meet the criteria and, if so, refer you to the local specialist service. Availability and waiting times vary significantly by area — some regions have well-established Tier 3 services, while others have limited provision.

Eligibility criteria

NICE recommends Wegovy for adults who meet all of the following:1

  • BMI of 35 or above with at least one weight-related comorbidity (such as Type 2 diabetes, high blood pressure, obstructive sleep apnoea, or cardiovascular disease)
  • OR BMI of 30–34.9 with comorbidities, where referral to specialist weight management services is appropriate under NICE obesity guidelines
  • For people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds, BMI thresholds are reduced by 2.5 points
  • Previous attempts at lifestyle modification (diet, exercise) have been insufficient

Treatment through Tier 3 services is typically for a maximum of 2 years, with stopping rules based on weight loss targets.

Cardiovascular risk reduction

In April 2026, NICE also recommended semaglutide for reducing the risk of heart attack, stroke, and cardiovascular death in people with BMI ≥27 who have established cardiovascular disease. This is based on the SELECT trial, which showed a 20% reduction in major cardiovascular events. This creates a second NHS pathway for accessing Wegovy for eligible patients with heart disease.2

The reality: waiting times and access

The biggest challenge with NHS access to Wegovy is the lack of Tier 3 capacity in many parts of England. Many areas have long waiting lists — often 6 months to over a year — and some regions have limited or no specialist weight management services at all. Even meeting the clinical criteria doesn't guarantee timely access.

This is why the majority of people currently using Wegovy in the UK access it through private prescriptions.

What if I can't access it on the NHS?

  • Private prescription: Costs £99–£299/month from regulated online prescribers. Typically requires BMI ≥30 or ≥27 with comorbidities. See our Wegovy cost guide
  • Consider Mounjaro: If you meet the GP rollout criteria, Mounjaro may be accessible through your GP practice sooner than Tier 3 Wegovy. See our Mounjaro NHS guide
  • Ask about NHS waiting lists: Even if there's a wait, getting on the list now means you'll be seen when capacity becomes available

Check your eligibility

Our quick checker covers both NHS and private criteria.

Check now →

Related articles

NHS Access

Can I Get Mounjaro on the NHS?

The phased GP rollout explained — cohorts, criteria, and timelines.

 Guide

NHS vs Private GLP-1 Prescriptions

Comparing the two access routes side by side.